Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 14727222.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We assessed all episodes of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at our hospital during a 12-month period (n=53) and compared those due to heterogeneous vancomycin-intermediate S. aureus (hVISA; n = 5, 9.4%) with those due to vancomycin-susceptible MRSA (n=48). Patients with hVISA bacteremia were more likely to have high bacterial load infections (P=.001), vancomycin treatment failure (persistent fever and bacteremia for >7 days after the start of therapy; P<.001), and initially low serum vancomycin levels (P=.006). These clinical markers of hVISA bacteremia may help focus diagnostic efforts and treatment.
Medical subject headings
- Bacteremia
- Methicillin Resistance
- Staphylococcal Infections
- Staphylococcus aureus
- Vancomycin